The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD4+ T-cell immunity predicts long-lasting antitumor immunity after PD-1 blockade therapy.
 
Kyoichi Kaira
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; MSD; Taiho Pharmaceutical
 
Ou Yamaguchi
Honoraria - Bristol-Myers Squibb
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical; Takeda
 
Atsuto Mouri
Honoraria - Bristol-Myers Squibb-Ono Pharmaceutical; Taiho Pharmaceutical
 
Ayako Shiono
No Relationships to Disclose
 
Fuyumi Nishihara
No Relationships to Disclose
 
Yu Miura
No Relationships to Disclose
 
Shun Shinomiya
No Relationships to Disclose
 
Kosuke Hashimoto
No Relationships to Disclose
 
Yoshitake Murayama
No Relationships to Disclose
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio
 
Kunihiko Kobayashi
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma
 
Hiroshi Kagamu
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Lilly; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - Immunicon
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)